Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Adverse drug reaction bulletin
| Adverse drug reaction bulletin |
| Pubbl/distr/stampa | Durham, Eng., : Adverse Drug Reaction Research Unit |
| Disciplina | 615.704 |
| Soggetto topico |
Drugs - Side effects
Drug-Related Side Effects and Adverse Reactions Médicaments - Effets secondaires |
| Soggetto genere / forma |
Periodical
periodicals. Periodicals. Périodiques. |
| ISSN | 2159-7774 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910763988003321 |
| Durham, Eng., : Adverse Drug Reaction Research Unit | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Adverse Events with Biomedicines : Prevention Through Understanding / / by Giuseppe Tridente
| Adverse Events with Biomedicines : Prevention Through Understanding / / by Giuseppe Tridente |
| Autore | Tridente Giuseppe |
| Edizione | [1st ed. 2014.] |
| Pubbl/distr/stampa | Milano : , : Springer Milan : , : Imprint : Springer, , 2014 |
| Descrizione fisica | 1 online resource (633 p.) |
| Disciplina | 615.704 |
| Soggetto topico |
Medicine
Pharmacy Biomedicine, general Medicine/Public Health, general |
| ISBN | 88-470-5313-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I General Aspects: 1 Introduction -- 2 Adverse drug events to biomedicines -- 3 Systemic syndromes caused by biomedicines -- Part II Monoclonal antibodies: 4 Monoclonal antibodies -- 5 Abciximab -- 6 Adalimumab -- 7 Alemtuzumab -- 8 Basiliximab -- 9 Belimumab -- 10 Bevacizumab -- 11 Brentuximab -- 12 Canakinumab -- 13 Catumaxomab -- 14. Certolizumab -- 15 Cetuximab -- 16 Daclizumab -- 17 Denosumab -- 18 Eculizumab -- 19 Edrecolomab -- 20 Efalizumab -- 21 Gemtuzumab -- 22 Golimumab -- 23 Ibritumomab -- 24 Infliximab -- 25 Ipilimumab -- 26 Muromonab -- 27 Natalizumab -- 28 Nimotuzumab -- 29 Ofatumumab -- 30 Omalizumab -- 31 Palivizumab -- 32 Panitumumab -- 33 Pertuzumab -- 34 Ranibizumab -- 35 Rituximab -- 36 Tocilizumab -- 37 Tositumomab -- 38 Trastuzumab -- 39 Ustekinumab -- Part III Fusion proteins: 40 Fusion proteins -- 41 Abatacept -- 42 Aflibercept -- 43 Alefacept -- 44 Belatacept -- 45 Etanercept -- 46 Rilonacept -- 47 Romiplostim -- Part IV Cytokines : 48 Cytokines -- 49 Interleukins -- 50 Denileukin-diftitox -- 51 Anakinra -- 52 Interferons -- 53 Hemopoietic stimulatory factors -- 54 Myelopoietic stimulatory factors -- 55 Thrombopoietic stimulatory factor -- 56 Pluripotent growth factors -- 57 Epidermal growth factors -- Part V Overview: 58 Biomedicines as adverse event inducers -- 59 Conclusions and perspectives. |
| Record Nr. | UNINA-9910298314403321 |
Tridente Giuseppe
|
||
| Milano : , : Springer Milan : , : Imprint : Springer, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
| Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
| Descrizione fisica | 1 online resource (506 p.) |
| Disciplina | 615.704 |
| Altri autori (Persone) |
VazRoy J
KlabundeThomas |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-282-78430-7
9786612784309 3-527-62147-4 3-527-62146-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction 2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates 2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity 2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation 3.5.1 Regulatory Guidance Documents |
| Record Nr. | UNINA-9910145982103321 |
| Weinheim, : Wiley-VCH | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
| Antitargets [[electronic resource] ] : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
| Descrizione fisica | 1 online resource (506 p.) |
| Disciplina | 615.704 |
| Altri autori (Persone) |
VazRoy J
KlabundeThomas |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships |
| ISBN |
1-282-78430-7
9786612784309 3-527-62147-4 3-527-62146-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction 2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates 2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity 2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation 3.5.1 Regulatory Guidance Documents |
| Record Nr. | UNINA-9910830632603321 |
| Weinheim, : Wiley-VCH | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antitargets : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde
| Antitargets : prediction and prevention of drug side effects / / edited by Roy J. Vaz and Thomas Klabunde |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH |
| Descrizione fisica | 1 online resource (506 p.) |
| Disciplina | 615.704 |
| Altri autori (Persone) |
VazRoy J
KlabundeThomas |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Drugs - Side effects
Drugs - Side effects - Prevention Drug interactions Drug development Drugs - Structure-activity relationships |
| ISBN |
1-282-78430-7
9786612784309 3-527-62147-4 3-527-62146-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antitargets; Contents; List of Contributors; Preface; I General Aspects; 1 Why Drugs Fail - A Study on Side Effects in New Chemical Entities; 1.1 Introduction; 1.2 Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically; 1.2.1 Amineptine; 1.2.2 Aminophenazone (Aminopyrine); 1.2.3 Astemizole; 1.2.4 Bromfenac Sodium; 1.2.5 Cerivastatin; 1.2.6 Chlormezanone; 1.2.7 Fenfluramine and Dexfenfluramine; 1.2.8 Flosequinan; 1.2.9 Glafenine; 1.2.10 Grepafloxacin; 1.2.11 Levacetylmethadol; 1.2.12 Mibefradil; 1.2.13 Rapacuronium Bromide; 1.2.14 Rofecoxib; 1.2.15 Temafloxacin
1.2.16 Troglitazone1.2.17 Ximelagatran; 1.3 Borderline Cases; 1.4 Investigational Drugs That Failed in Clinical Phases from 1992 to 2002; 1.4.1 A Case Study: Fialuridine; 1.4.2 A Recent Case Study: Torcetrapib; 1.4.3 General Reasons for Project Failing in Clinical Phases I-III; 1.5 Strategies for Avoiding Failure; 1.6 An Unusual Case: The Revival of Thalidomide; References; 2 Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure-In Vitro (Pharmacology-ADME)-In Vivo (Safety) Relationships; 2.1 Introduction 2.1.1 Biological Profiling/Fingerprints and Drug Discovery Applications2.1.2 Polypharmacology of Drugs; 2.2 The BioPrint(®) Approach; 2.2.1 BioPrint(®) - General; 2.2.2 BioPrint(®) Assay Selection and Profile Description; 2.2.3 Compounds in BioPrint(®); 2.2.4 BioPrint(®) In Vivo Data sets; 2.2.4.1 Compound Details; 2.2.4.2 ADR Data; 2.2.4.3 Pharmacokinetics; 2.2.4.4 Toxicity Data; 2.3 Structure-In Vitro Relationships; 2.3.1 Similarity, Chemotypes - What Is a Biologically Relevant Descriptor?; 2.3.2 Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates 2.3.2.1 Differentiation of Leads2.3.2.2 Analysis of Attrited Compounds; 2.3.3 Structural versus Experimental Differentiation - Dependence on Structure-Derived Descriptor Used; 2.3.4 Predictive Models from Pharmacological Data; 2.3.5 Predictive Models from ADME Data - BioPrint(®) Learnings; 2.4 Chemogenomic Analysis - Target-Target Relationships; 2.5 In Vitro-In Vivo Relationships - Placing Drug Candidates in the Context of BioPrint(®); 2.5.1 Analyzing Potential ADR Liabilities Based on Individual Hits; 2.5.2 Analyzing Potential ADR Liabilities Based on Profile Similarity 2.6 A Perspective for the FutureReferences; II Antitargets: Ion Channels and GPCRs; 3 Pharmacological and Regulatory Aspects of QT Prolongation; 3.1 Introduction; 3.2 hERG: Target Versus Antitarget; 3.3 Pharmacology of QT Prolongation; 3.3.1 Multiple Mechanisms Leading to QT Prolongation; 3.3.2 hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome; 3.3.3 Pharmacogenetic Aspects; 3.4 Significance of Drug-Induced QT Prolongation; 3.4.1 Prolonged QT/QTc and Occurrence of TdP; 3.4.2 Dose-Response Relationship for QT Prolongation; 3.5 Regulatory Aspects of QT Prolongation 3.5.1 Regulatory Guidance Documents |
| Record Nr. | UNINA-9910877316903321 |
| Weinheim, : Wiley-VCH | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Atlas of drug reactions / R. Douglas Collins
| Atlas of drug reactions / R. Douglas Collins |
| Autore | Collins, R. Douglas |
| Pubbl/distr/stampa | New York : Churchill Livingstone, 1985 |
| Descrizione fisica | 419 p. : ill. ; 27 cm |
| Disciplina | 615.704 |
| Soggetto non controllato |
Farmaci - Effetti collaterali
Farmaci - Interazione Farmaci - Tossicità |
| ISBN | 0-443-08377-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-990008287970403321 |
|
Collins, R. Douglas
|
||
| New York : Churchill Livingstone, 1985 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Detection and prevention of adverse drug events [[electronic resource] ] : information technologies and human factors / / edited by Regis Beuscart, Werner Hackl, Christian Nohr
| Detection and prevention of adverse drug events [[electronic resource] ] : information technologies and human factors / / edited by Regis Beuscart, Werner Hackl, Christian Nohr |
| Pubbl/distr/stampa | Amsterdam ; ; Washington D.C., : IOS Press, c2009 |
| Descrizione fisica | 1 online resource (236 p.) |
| Disciplina |
615.704
615/.10289 |
| Altri autori (Persone) |
BeuscartRégis
HacklWerner <1976-> NøhrChristian |
| Collana | Studies in health technology and informatics |
| Soggetto topico |
Hospitals - Drug distribution systems
Drugs - Side effects Medication errors |
| Soggetto genere / forma | Electronic books. |
| ISBN |
661245461X
1-282-45461-7 9786612454615 1-60750-455-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Title page; Preface; Contents; Part A. Keynotes on Patient Safety; Measuring Patient Safety: The Need for Prospective Detection of Adverse Events; The Impact of Commercial Electronic Medication Management Systems on Errors and Clinicians' Work in Hospitals; Patient Safety Through Intelligent Procedures in Medication: The PSIP Project; Human Factors Engineering for Computer-Supported Identification and Prevention of Adverse Drug Events; Decision Support to Avoid Medication Errors . How Far Have We Come in Denmark and What Are the Present Challenges
ReMINE: An Ontology-Based Risk Management PlatformThe EU-ADR Project: Preliminary Results and Perspective; DebugIT: Building a European Distributed Clinical Data Mining Network to Foster the Fight Against Microbial Diseases; Part B. Detection and Prevention of Adverse Drug Events; Detection of Adverse Drug Events: Proposal of a Data Model; Detection of Adverse Drug Events Detection: Data Agregation and Data Mining; The Expert Explorer: A Tool for Hospital Data Visualization and Adverse Drug Event Rules Validation; Application of the Apriori Algorithm for Adverse Drug Reaction Detection Adverse Drug Events Prevention Rules: Multi-Site Evaluation of Rules from Various SourcesAutomatic Indexing in a Drug Information Portal; Implementation of SNOMED CT to the Medicines Database of a General Hospital; A Knowledge Engineering Framework Towards Clinical Support for Adverse Drug Event Prevention: The PSIP Approach; Strategy for Implementation and First Results of Advanced Clinical Decision Support in Hospital Pharmacy Practice Inevitable Components of and Steps for ADE Management Systems: The Need for a Unified Ontological Framework (UOF) and a More Effective Collaboration in Medication SafetyComputerised Physician Order Entry (CPOE); Part C. Human Factors and Adverse Drug Events; CPOE, Alerts and Workflow: Taking Stock of Ten Years Research at Erasmus MC; Contribution of Human Factors for the Review of Automatically Detected ADE; A Framework for Diagnosing and Identifying Where Technology-Induced Errors Come from; Gaming Against Medical Errors: Methods and Results from a Design Game on CPOE The PSIP Approach to Account for Human Factors in Adverse Drug Events: Preliminary Field StudiesThe Problem of Defensive Medicine: Two Italian Surveys; Subject Index; Author Index |
| Record Nr. | UNINA-9910457128203321 |
| Amsterdam ; ; Washington D.C., : IOS Press, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Detection and prevention of adverse drug events [[electronic resource] ] : information technologies and human factors / / edited by Regis Beuscart, Werner Hackl, Christian Nohr
| Detection and prevention of adverse drug events [[electronic resource] ] : information technologies and human factors / / edited by Regis Beuscart, Werner Hackl, Christian Nohr |
| Pubbl/distr/stampa | Amsterdam ; ; Washington D.C., : IOS Press, c2009 |
| Descrizione fisica | 1 online resource (236 p.) |
| Disciplina |
615.704
615/.10289 |
| Altri autori (Persone) |
BeuscartRégis
HacklWerner <1976-> NøhrChristian |
| Collana | Studies in health technology and informatics |
| Soggetto topico |
Hospitals - Drug distribution systems
Drugs - Side effects Medication errors |
| ISBN |
661245461X
1-282-45461-7 9786612454615 1-60750-455-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Title page; Preface; Contents; Part A. Keynotes on Patient Safety; Measuring Patient Safety: The Need for Prospective Detection of Adverse Events; The Impact of Commercial Electronic Medication Management Systems on Errors and Clinicians' Work in Hospitals; Patient Safety Through Intelligent Procedures in Medication: The PSIP Project; Human Factors Engineering for Computer-Supported Identification and Prevention of Adverse Drug Events; Decision Support to Avoid Medication Errors . How Far Have We Come in Denmark and What Are the Present Challenges
ReMINE: An Ontology-Based Risk Management PlatformThe EU-ADR Project: Preliminary Results and Perspective; DebugIT: Building a European Distributed Clinical Data Mining Network to Foster the Fight Against Microbial Diseases; Part B. Detection and Prevention of Adverse Drug Events; Detection of Adverse Drug Events: Proposal of a Data Model; Detection of Adverse Drug Events Detection: Data Agregation and Data Mining; The Expert Explorer: A Tool for Hospital Data Visualization and Adverse Drug Event Rules Validation; Application of the Apriori Algorithm for Adverse Drug Reaction Detection Adverse Drug Events Prevention Rules: Multi-Site Evaluation of Rules from Various SourcesAutomatic Indexing in a Drug Information Portal; Implementation of SNOMED CT to the Medicines Database of a General Hospital; A Knowledge Engineering Framework Towards Clinical Support for Adverse Drug Event Prevention: The PSIP Approach; Strategy for Implementation and First Results of Advanced Clinical Decision Support in Hospital Pharmacy Practice Inevitable Components of and Steps for ADE Management Systems: The Need for a Unified Ontological Framework (UOF) and a More Effective Collaboration in Medication SafetyComputerised Physician Order Entry (CPOE); Part C. Human Factors and Adverse Drug Events; CPOE, Alerts and Workflow: Taking Stock of Ten Years Research at Erasmus MC; Contribution of Human Factors for the Review of Automatically Detected ADE; A Framework for Diagnosing and Identifying Where Technology-Induced Errors Come from; Gaming Against Medical Errors: Methods and Results from a Design Game on CPOE The PSIP Approach to Account for Human Factors in Adverse Drug Events: Preliminary Field StudiesThe Problem of Defensive Medicine: Two Italian Surveys; Subject Index; Author Index |
| Record Nr. | UNINA-9910781059603321 |
| Amsterdam ; ; Washington D.C., : IOS Press, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Detection and prevention of adverse drug events : information technologies and human factors / / edited by Regis Beuscart, Werner Hackl, Christian Nohr
| Detection and prevention of adverse drug events : information technologies and human factors / / edited by Regis Beuscart, Werner Hackl, Christian Nohr |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Amsterdam ; ; Washington D.C., : IOS Press, c2009 |
| Descrizione fisica | 1 online resource (236 p.) |
| Disciplina |
615.704
615/.10289 |
| Altri autori (Persone) |
BeuscartRegis
HacklWerner <1976-> NhrChristian |
| Collana | Studies in health technology and informatics |
| Soggetto topico |
Hospitals - Drug distribution systems
Drugs - Side effects Medication errors |
| ISBN |
661245461X
1-282-45461-7 9786612454615 1-60750-455-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Title page; Preface; Contents; Part A. Keynotes on Patient Safety; Measuring Patient Safety: The Need for Prospective Detection of Adverse Events; The Impact of Commercial Electronic Medication Management Systems on Errors and Clinicians' Work in Hospitals; Patient Safety Through Intelligent Procedures in Medication: The PSIP Project; Human Factors Engineering for Computer-Supported Identification and Prevention of Adverse Drug Events; Decision Support to Avoid Medication Errors . How Far Have We Come in Denmark and What Are the Present Challenges
ReMINE: An Ontology-Based Risk Management PlatformThe EU-ADR Project: Preliminary Results and Perspective; DebugIT: Building a European Distributed Clinical Data Mining Network to Foster the Fight Against Microbial Diseases; Part B. Detection and Prevention of Adverse Drug Events; Detection of Adverse Drug Events: Proposal of a Data Model; Detection of Adverse Drug Events Detection: Data Agregation and Data Mining; The Expert Explorer: A Tool for Hospital Data Visualization and Adverse Drug Event Rules Validation; Application of the Apriori Algorithm for Adverse Drug Reaction Detection Adverse Drug Events Prevention Rules: Multi-Site Evaluation of Rules from Various SourcesAutomatic Indexing in a Drug Information Portal; Implementation of SNOMED CT to the Medicines Database of a General Hospital; A Knowledge Engineering Framework Towards Clinical Support for Adverse Drug Event Prevention: The PSIP Approach; Strategy for Implementation and First Results of Advanced Clinical Decision Support in Hospital Pharmacy Practice Inevitable Components of and Steps for ADE Management Systems: The Need for a Unified Ontological Framework (UOF) and a More Effective Collaboration in Medication SafetyComputerised Physician Order Entry (CPOE); Part C. Human Factors and Adverse Drug Events; CPOE, Alerts and Workflow: Taking Stock of Ten Years Research at Erasmus MC; Contribution of Human Factors for the Review of Automatically Detected ADE; A Framework for Diagnosing and Identifying Where Technology-Induced Errors Come from; Gaming Against Medical Errors: Methods and Results from a Design Game on CPOE The PSIP Approach to Account for Human Factors in Adverse Drug Events: Preliminary Field StudiesThe Problem of Defensive Medicine: Two Italian Surveys; Subject Index; Author Index |
| Record Nr. | UNINA-9910827027703321 |
| Amsterdam ; ; Washington D.C., : IOS Press, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Farmaci antibatterici / Giovanni Greco
| Farmaci antibatterici / Giovanni Greco |
| Autore | Greco, Giovanni <docente di chimica farmaceutica> |
| Pubbl/distr/stampa | [Napoli] : Loghia, [2009] |
| Descrizione fisica | 144 p. ; 24 cm |
| Disciplina | 615.704 |
| Soggetto non controllato |
Antibatterici
Antibiotici |
| ISBN | 978-88-95122-16-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | ita |
| Record Nr. | UNINA-990009650600403321 |
|
Greco, Giovanni <docente di chimica farmaceutica>
|
||
| [Napoli] : Loghia, [2009] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
